drugset / Trial / NCT05359861
Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This was a Phase 2 trial composed of an open label Lead-In followed by a planned Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo (inactive substance) in combination with atezolizumab plus bevacizumab in patients with first-line advanced or metastatic HCC. Only the Lead-In Phase of the study was completed.
Timeline
- Start
- 2022-04-12
- Primary completion
- 2025-06-30
- Completion
- 2025-07-08
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Casdozokitug | Monoclonal antibody | — | Intravenous |
| Background | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |